ER+ Breast Cancer

Business news, market intelligence, and global industry analysis.

The Latest

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

Representative image of targeted estrogen receptor degradation using PROTAC technology in ESR1-mutant breast cancer cells.

Can vepdegestrant outperform elacestrant in the race for ESR1-mutant breast cancer dominance?

Vepdegestrant shows stronger PFS benefit than elacestrant in ESR1-mutant breast cancer. Can it become the new standard? Explore data, safety, and market outlook.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

June 10, 2025